Major Depressive Disorder (MDD): Lifting the Fog

Major Depressive Disorder is a common, often recurrent illness characterised by low mood, anhedonia, and a host of cognitive-somatic symptoms that impair daily life. DSM-5-TR requires ≥ 5 symptoms for ≥ 2 weeks, including either depressed mood or loss of interest, plus distress/impairment . Despite effective treatments, depression remains a leading global cause of disability with ~280 million cases worldwide .

Table of Contents

  1. Diagnostic Criteria
  2. Prevalence & Burden
  3. Etiology & Neurobiology
  4. Risk Factors
  5. Assessment Tools
  6. Evidence-Based Treatments
  7. Emerging & Adjunctive Options
  8. Key Takeaways

Diagnostic Criteria

DSM-5-TR checklist (abridged):

  • Mood: depressed most of the day
  • Interest: markedly diminished pleasure
  • Weight/appetite, sleep, psychomotor, fatigue changes
  • Worthlessness/guilt, concentration problems
  • Recurrent death/suicidal thoughts
    Symptoms must be new/worsened, present most of the day, nearly every day, ≥ 2 weeks, and not better explained by substances or medical illness .

Prevalence & Burden

Scope Estimate
Lifetime prevalence ~ 8 % (high-income); 10 – 15 % in many countries
Point prevalence 3.8 % globally; 5 % of adults per WHO
U.S. 2021 severe episode 14.5 million adults (5.7 %)
DALYs Top three worldwide in 18–44 y group

COVID-19 era analyses show a 35 % increase in depressive symptoms, especially among youth and women .

Etiology & Neurobiology

Domain Key Findings
Genetics SNP-based heritability ≈ 37 %; polygenic overlap with anxiety, bipolar.
Monoamine dysregulation Serotonin, norepinephrine, dopamine deficits underpin SSRI/SNRI efficacy.
Neural circuits Hyper-active amygdala; hypo-active dorsolateral prefrontal cortex—impaired emotion regulation; aberrant default-mode connectivity .
Neuroinflammation Elevated CRP, IL-6 in a subset (“inflamed depression”).
HPA-axis Cortisol hyper-secretion, hippocampal atrophy on MRI.

Risk Factors

  • Biological: female sex hormones, chronic illness, family history
  • Psychological: neuroticism, negative cognitive style
  • Social: childhood adversity, poverty, loneliness, discrimination
  • Recent stressors: bereavement, job loss, postpartum period

Assessment Tools

Instrument Use
PHQ-9 Primary-care screening & severity (0–27)
Hamilton Depression Rating Scale (HAM-D-17) Research gold standard
Beck Depression Inventory-II Self-report depth
Columbia-Suicide Severity Rating Scale Suicide-risk adjunct

Rule out bipolar (e.g., MDQ), substance mood disorder, hypothyroidism.

Self-assessment: PHQ-9 · DASS-21

Evidence-Based Treatments

1. psychotherapy

Modality Evidence
Cognitive Behavioural Therapy (CBT) Large effect vs. controls; meta-analysis confirms durability
Interpersonal Therapy (IPT) Comparable to CBT for mild-moderate MDD
Behavioral Activation Simpler, equally effective in pragmatic trials

Internet-delivered CBT shows non-inferior outcomes for moderate MDD.

2. Pharmacotherapy

Class Examples Notes
SSRIs fluoxetine, sertraline First-line; ~60 % response
SNRIs venlafaxine, duloxetine Helpful for pain comorbidity
Atypical bupropion (NDRI); mirtazapine Weight/appetite, sexual-side-effect profiles
Adjuncts atypical antipsychotics (aripiprazole), lithium, T3 For partial response

3. Combination Therapy

CBT + antidepressant outperforms either alone in chronic/severe cases .

4. Neuro-stimulation

  • rTMS (FDA-cleared): provides response in ~50 % of treatment-resistant cases; recent reviews refine protocols .
  • ECT: gold-standard for psychotic or suicidal depression (80 % response).
  • tDCS: modest effect, home units under study.

Emerging & Adjunctive Options

Modality Status & Highlights
Esketamine nasal spray (Spravato) FDA 2019 TRD approval; rapid reduction in suicidality
Zuranolone (Zurzuvae) First oral neuroactive steroid; FDA 2023 postpartum-depression approval
Psilocybin-assisted therapy 25 mg single-dose + support shows significant MADRS drop in Phase 2 study
Ketamine IV Off-label; rapid but transient—bridge to standard therapy
Deep-brain Stimulation Subcallosal cingulate target in pivotal trials
Digital CBT & AI chatbots Scalable, early outcomes promising

Lifestyle: sleep hygiene, exercise (moderate-vigorous 150 min/wk), Mediterranean diet—all show adjunctive benefit.

Key Takeaways

  1. Depression is common (~280 million cases) and disabling, yet eminently treatable.
  2. Monoamine, neuro-circuit, and inflammatory pathways interact with psychosocial stress to produce symptoms.
  3. CBT/IPT and SSRIs/SNRIs are first-line; combining them boosts remission.
  4. Treatment-resistant options now include esketamine, zuranolone, rTMS, ECT, and investigational psychedelics.
  5. Early detection, patient-centred choice, and stepped-care models maximise recovery and prevent recurrence.